logo-loader

ImmuPharma drug could still have a role in treating lupus – City analyst

Published: 16:15 17 Apr 2018 BST

ImmuPharma PLC (LON:IMM) drug Lupuzor needs further analysis and certainly isn’t a bust, according to Vadim Alexandre, analyst at Northland Capital.

With shares down sharply, the reaction to phase III trial results for the lupus drug has been “knee-jerk” and probably not fully reflective of the outlook for the treatment, he said in an interview with Proactive’s Andrew Scott.

ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug...

ImmuPharma PLC (AIM:IMM) chief executive Tim McCarthy provides an extensive update during an interview with Proactive's Stephen Gunnion, focusing on the financial, business, and portfolio developments of the company. McCarthy clarified that the company is in a strong financial position,...

3 weeks, 1 day ago